Scarica l'app Stockscreener
37.73
0.68%
-0.26
Dopo l'orario di chiusura:
37.40
-0.33
-0.87%
Definium Therapeutics Inc Borsa (DFTX) Ultime notizie
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 - BioSpace
Definium Therapeutics (DFTX) Showcases Phase 3 Data Amid High Va - GuruFocus
DFTXDefinium Therapeutics Inc Revenue Breakdown - Finviz
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics CEO Robert Barrow Sells 19,023 Shares Following 40,000-Share Award - Kalkine Media
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics Secures Second FDA Breakthrough Therapy Designation for DT120 in MDD - Minichart
Definium Therapeutics Gains FDA Breakthrough for Depression Drug - TipRanks
Definium Therapeutics (DFTX) Gains FDA Breakthrough Therapy Desi - GuruFocus
Definium Therapeutics receives FDA Breakthrough Therapy designation for DT120 ODT in MDD after positive Phase 3 - TradingView
Single LSD tablet in Definium Therapeutics (DFTX) trial shows 12-week benefit in major depression - Stock Titan
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results - Business Wire
Definium Therapeutics Stock (DFTX) Opinions on Analyst Upgrade and Regulatory Progress - Moomoo
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares - Investing.com
Definium Therapeutics (DFTX) CEO gets 40K-share award, sells stock for taxes - Stock Titan
Definium Therapeutics, Inc. (NASDAQ: DFTX) Stock Price, News & Analysis - Kalkine
Transcript : Definium Therapeutics, Inc.Special Call - marketscreener.com
After $1.23M sale, Definium Therapeutics (DFTX) holder plans another stock trade - Stock Titan
Stifel reiterates Buy on Definium Therapeutics stock, $60 target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on Definium Therapeutics stock, $60 target - Investing.com
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Definium Therapeutics Announces New Employee Inducement Grants - The Chronicle-Journal
Wells Fargo Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $72 - moomoo.com
Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Stifel confident in Definium Therapeutics stock after management dinner By Investing.com - Investing.com Nigeria
Stifel confident in Definium Therapeutics stock after management dinner - Investing.com
SW Weekly: Why I Can't Buy Definium Following Phase 3 LSD Readout. (NASDAQ:DFTX) - Seeking Alpha
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events - Business Wire
Certain Common Shares of Definium Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-AUG-2026. - marketscreener.com
Certain Warrants of Definium Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-AUG-2026. - marketscreener.com
DRIEHAUS CAPITAL MANAGEMENT LLC Expands Definium Therapeutics In - GuruFocus
Traders Purchase High Volume of Definium Therapeutics Call Options (NASDAQ:DFTX) - MarketBeat
Definium Therapeutics (DFTX) Could Be 22% Undervalued On Positive Phase 3 Voyage Results - Sahm
Total non-current assets of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
Definium Therapeutics Posts Strong Phase 3 GAD Data for DT120 - TipRanks
Definium Therapeutics (NASDAQ:DFTX) Coverage Initiated by Analysts at Bank of America - MarketBeat
Definium Therapeutics (DFTX) Is Down 5.6% After Positive Phase 3 GAD Data For DT120 ODT - Sahm
DFTX Initiates Coverage On B of A Securities -- Rating Set to Bu - GuruFocus
BofA initiates Definium Therapeutics stock with buy on psychedelic drug potential - Investing.com Nigeria
Definium Therapeutics (DFTX) Reports Positive Phase 3 GAD Trial Results Amid High Valuation - GuruFocus
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):